These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 10773550)

  • 21. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
    Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
    Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26.
    Watanabe N; Oriuchi N; Sugiyama S; Kuroki M; Matsuoka Y; Tanada S; Murata H; Inoue T; Sasaki Y
    Nuklearmedizin; 1999; 38(4):115-9. PubMed ID: 10392376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental radioimmunotherapy of a xenografted human glioma using 131I-labeled monoclonal antibody to epidermal growth factor receptor.
    Takahashi H; Nakazawa S; Herlyn D
    Neurol Med Chir (Tokyo); 1993 Sep; 33(9):610-5. PubMed ID: 7505399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical recognition of the epidermal growth factor receptor by the h-R3 antibody in the skin of experimental animals.
    Maceira M; Rengifo E; Cedeño M; Merino N; Casacó Parada A
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):360-3. PubMed ID: 15536338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy.
    Ramos-Suzarte M; Rodríguez N; Oliva JP; Iznaga-Escobar N; Perera A; Morales A; Gonzalez N; Cordero M; Torres L; Pimentel G; Borrón M; González J; Torres O; Rodríguez T; Pérez R
    J Nucl Med; 1999 May; 40(5):768-75. PubMed ID: 10319748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas.
    Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D
    Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor targeting using anti-epidermal growth factor receptor (ior egf/r3) immunoconjugate with a tetraaza macrocyclic agent (DO3A-EA).
    Mishra G; Panwar P; Mishra AK
    Mol Imaging; 2012; 11(5):408-16. PubMed ID: 22954185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Technetium-99m-labeled anti-EGF-receptor antibody in patients with tumor of epithelial origin: I. Biodistribution and dosimetry for radioimmunotherapy.
    Iznaga-Escobar N; Torres LA; Morales A; Ramos M; Alvarez I; Pérez N; Fraxedas R; Rodríguez O; Rodríguez N; Pérez R; Lage A; Stabin MG
    J Nucl Med; 1998 Jan; 39(1):15-23. PubMed ID: 9443731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer.
    Sampath L; Kwon S; Ke S; Wang W; Schiff R; Mawad ME; Sevick-Muraca EM
    J Nucl Med; 2007 Sep; 48(9):1501-10. PubMed ID: 17785729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of a new DTPA-derivative chelator: comparative biodistribution and imaging studies of 111In-labeled B3 monoclonal antibody in athymic mice bearing human epidermoid carcinoma xenografts.
    Camera L; Kinuya S; Garmestani K; Pai LH; Brechbiel MW; Gansow OA; Paik CH; Pastan I; Carrasquillo JA
    Nucl Med Biol; 1993 Nov; 20(8):955-62. PubMed ID: 8298575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425.
    Senekowitsch-Schmidtke R; Steiner K; Haunschild J; Möllenstädt S; Truckenbrodt R
    Cancer Immunol Immunother; 1996 Feb; 42(2):108-14. PubMed ID: 8620519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab.
    Pool M; Kol A; Lub-de Hooge MN; Gerdes CA; de Jong S; de Vries EG; Terwisscha van Scheltinga AG
    Oncotarget; 2016 Oct; 7(42):68111-68121. PubMed ID: 27602494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potencial theranostic agent for EGF-R expression tumors: (177)Lu-DOTA-nimotuzumab.
    Calzada V; Zhang X; Fernandez M; Diaz-Miqueli A; Iznaga-Escobar N; Deutscher SL; Balter H; Quinn TP; Cabral P
    Curr Radiopharm; 2012 Oct; 5(4):318-24. PubMed ID: 22280117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.
    Orlova A; Wållberg H; Stone-Elander S; Tolmachev V
    J Nucl Med; 2009 Mar; 50(3):417-25. PubMed ID: 19223403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies.
    Masui H; Kawamoto T; Sato JD; Wolf B; Sato G; Mendelsohn J
    Cancer Res; 1984 Mar; 44(3):1002-7. PubMed ID: 6318979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice.
    Morelli D; Ménard S; Pozzi B; Balsari A; Colnaghi MI
    Cell Biophys; 1994; 24-25():119-26. PubMed ID: 7736515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A CDR-grafted (humanized) domain-deleted antitumor antibody.
    Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
    Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 188Re-labeled anti-epidermal growth factor receptor humanized monoclonal antibody h-R3: labeling conditions, in vitro and in vivo stability.
    Iznaga-Escobar N; Ramirez IL; Izquierdo JC; Suárez L; Morales D; Pérez-Rodríguez R
    Methods Find Exp Clin Pharmacol; 2003 Nov; 25(9):703-11. PubMed ID: 14685297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Direct and indirect labeling with 99mTc of an antireceptor monoclonal antibody of EGF].
    Calderón Sánchez O; Zayas Crespo F; Leyva Montaña R; Beckford Vera D; Gómez JA
    Rev Esp Med Nucl; 2005; 24(1):38-44. PubMed ID: 15701345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats.
    Iznaga Escobar N; Morales AM; Ducongé J; Torres IC; Fernández E; Gómez JA
    Nucl Med Biol; 1998 Jan; 25(1):17-23. PubMed ID: 9466357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.